Ma, C. 2023. Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?. Canadian IBD Today. 1, S05 (May 2023), 2–7. DOI:https://doi.org/10.58931/cibdt.2023.1S0510.